A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
Urinary Bladder Neoplasms|Receptors, Fibroblast Growth Factor
DRUG: Erdafitinib Intravesical Delivery System
Number of Participants with Dose-limiting Toxicity (DLT), Number of participants with DLT will be assessed. The DLTs are specific adverse events related to erdafitinib intravesical delivery system and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity., Up to 28 days
Plasma Concentration of Erdafitinib, Plasma concentration of erdafitinib will be reported., Up to 180 days|Urine Concentration of Erdafitinib, Urine concentration of erdafitinib will be reported., Up to 180 days|Number of Participants with Adverse Events (AEs), An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product., Up to 3 years 10 months|Number of Participants with AEs by Severity, Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event., Up to 3 years 10 months
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.